Transient impairment of olfactory threshold in acute multiple sclerosis relapse

•We present a prospective study on olfactory threshold in acute MS relapse.•Threshold was assessed at baseline and after 4, 12 and 24 weeks.•Threshold is impaired in MS relapse compared to stable MS at all timepoints.•Threshold impairment seems to be a transient bystander feature of MS relapse.•Thre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis and related disorders Jg. 23; S. 74 - 77
Hauptverfasser: Bsteh, Gabriel, Hegen, Harald, Ladstätter, Felix, Berek, Klaus, Amprosi, Matthias, Wurth, Sebastian, Auer, Michael, Di Pauli, Franziska, Deisenhammer, Florian, Lutterotti, Andreas, Berger, Thomas
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands Elsevier B.V 01.07.2018
Schlagworte:
Biomarker
Development
Multiple sclerosis
Olfactory threshold
Relapse
Time
Olfactory threshold
Development
Multiple sclerosis
Relapse
Biomarker
Time
ISSN:2211-0348, 2211-0356, 2211-0356
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•We present a prospective study on olfactory threshold in acute MS relapse.•Threshold was assessed at baseline and after 4, 12 and 24 weeks.•Threshold is impaired in MS relapse compared to stable MS at all timepoints.•Threshold impairment seems to be a transient bystander feature of MS relapse.•Threshold impairment might be a biomarker of the level of CNS inflammation. Impairment of olfactory threshold is a feature of early and active relapsing remitting multiple sclerosis (RRMS). It predicts inflammatory disease activity and was reported to be transient. However, the timing of onset and resolve of olfactory threshold impairment remains unclear. To prospectively assess the development of olfactory threshold in acute MS relapse over time in comparison to stable MS patients. In a prospective observational design, we measured olfactory threshold by performing the Sniffin’ Sticks test (minimum score 0, maximum score 16 reflecting optimal olfactory function) at baseline and after 4, 12 and 24 weeks. We included 30 RRMS patients with acute MS relapse and 30 clinically stable RRMS patients (defined as no relapse within the last 12 months) as a control group. Olfactory threshold was impaired in patients with acute MS relapse at baseline (median difference = −3.5; inter-quartile range [IQR] −4.5– − 2.5; p < 0.001), week 4 (−2.5; IQR −3.0 – −2.0; p < 0.001), week 12 (−1.5; IQR −2.0 – −0.5; p = 0.002) and week 24 (−0.5; IQR −1.0 – 0.0; p = 0.159) compared to stable MS patients. Of note, in relapsing patients in whom disease-modifying treatment was initiated or escalated after relapse, threshold did not differ anymore from stable patients at week 12 (−0.5; IQR −1.0 – 0.5; p = 0.247) and week 24 (0.0; IQR −1.0 – 1.0; p = 0.753). Olfactory threshold impairment seems to be a transient bystander feature of MS relapse. It may be correlated to the level of inflammation within the CNS and might be a useful biomarker in this regard.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:2211-0348
2211-0356
2211-0356
DOI:10.1016/j.msard.2018.05.006